| ²é¿´: 567 | »Ø¸´: 1 | ||
| ±¾Ìû²úÉú 1 ¸ö ·ÒëEPI £¬µã»÷ÕâÀï½øÐв鿴 | ||
swlhlbrгæ (³õÈëÎÄ̳)
|
[ÇóÖú]
´óÉñ°ï°ïæ~°ïÎÒ·ÒëÒ»ÏÂÖÐÎÄÕªÒª£¨300×Ö£©~·Ç³£¸Ðл~
|
|
|
Ä¿µÄ£ºÍ¨¹ý½«ÃÅÕï·¢ÉúµÄÒ©Æ·²»Á¼·´Ó¦¼ÆÈëÃÅÕïµç×Ó²¡Àú£¬±£Ö¤ÃÅÕïËù·¢ÉúÒ©Æ·²»Á¼·´Ó¦µÄ¿É×·ËÝÐÔ£¬ÔÚ¼ÓÇ¿ÁÙ´²¸öÌ廯ÓÃÒ©°²È«µÄͬʱ´Ù½ø¶ÔÉÏÊÐÒ©Æ·µÄ°²È«ÖÊÁ¿¼à¿Ø£¬±£ÕϹã´ó»¼ÕßµÄÓÃÒ©°²È«¡£·½·¨£º³ÉÁ¢Æ·¹ÜȦ»î¶¯Ð¡×飬×ñÑPDCA³ÌÐò£¬»îÓÃÆ·¹ÜȦÆß´óÊÖ·¨£¬·ÖÎöÃÅÕïÒ©Æ·²»Á¼·´Ó¦ÄÑÒÔËÝÔ´µÄÔÒò£¬Ì½Ë÷¶Ô²ß£¬ÓèÒÔʵʩ²¢ÆÀ¹À»î¶¯Ð§¹û¡£ ½á¹û£º±È½Ï»î¶¯Ç°¡¢ºó¸÷ÏîÒ©Æ·²»Á¼·´Ó¦¿ÉËÝÔ´Ö¸±ê¾ùµÃµ½ÁËÃ÷ÏÔ¸ÄÉÆ£¬ÃÅÕïÒ©Æ·²»Á¼·´Ó¦¼ÆÈ벡ÀúÂÊÓɸÄÉÆÇ°31%ÉýÖÁ¸ÄÉÆºó90.1%£¬»î¶¯ºóÃÅÕïÍËÒ©µÇ¼Ç±íÈ·ÈÏÇ©ÃûÂÊ´ï87.2%£¬»î¶¯´ï±êÂÊΪ105.6%¡£½áÂÛ£º±¾´ÎÆ·¹ÜȦ»î¶¯ÓÐЧµÄÌá¸ßÁËÃÅÕïÒ©Æ·²»Á¼·´Ó¦¼ÆÈ벡ÀúµÄÖÊÁ¿£¬»¼Õß³ÐŵǩÃûÒ»¶¨³Ì¶ÈµÄ±£Ö¤ÁËÃÅÕïÒ©Æ·²»Á¼·´Ó¦µÄÕæÊµÐÔ£¬±£Ö¤ÁËÃÅÕïÒ©Æ·²»Á¼·´Ó¦µÄ¿ÉËÝÔ´ÐÔ£¬ÎªÒ©Æ·µÄÁÙ´²ºÏÀíʹÓÃÌṩÁËÒÀ¾Ý¡£ ¹Ø¼ü´Ê£ºÒ©Æ·²»Á¼·´Ó¦£¬Æ·¹ÜȦ£¬ËÝÔ´ |
» ²ÂÄãϲ»¶
085600²ÄÁÏÓ뻯¹¤301·ÖÇóµ÷¼ÁԺУ
ÒѾÓÐ5È˻ظ´
081700£¬311£¬Çóµ÷¼Á
ÒѾÓÐ15È˻ظ´
Ò»Ö¾Ô¸±±¾©»¯¹¤085600 310·ÖÇóµ÷¼Á
ÒѾÓÐ18È˻ظ´
²ÄÁÏÓ뻯¹¤371Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
336²ÄÁÏÓ뻯¹¤085600Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
²ÄÁÏ334Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
331Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
332Çóµ÷¼Á
ÒѾÓÐ17È˻ظ´
Ò»Ö¾Ô¸ÄϾ©º½¿Õº½Ìì´óѧ ²ÄÁÏÓ뻯¹¤329·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
²ÄÁÏר˶322
ÒѾÓÐ7È˻ظ´
Î人һÐÄÒ»Òë
¾èÖú¹ó±ö (ÖøÃûдÊÖ)
- ·ÒëEPI: 502
- Ó¦Öú: 8 (Ó×¶ùÔ°)
- ½ð±Ò: 2283.1
- É¢½ð: 5914
- ºì»¨: 32
- Ìû×Ó: 1665
- ÔÚÏß: 321.9Сʱ
- ³æºÅ: 3587652
- ×¢²á: 2014-12-10
- ÐÔ±ð: GG
- רҵ: ¸ß·Ö×Ӻϳɻ¯Ñ§
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
É̼ÒÒѾÖ÷¶¯ÉùÃ÷´Ë»ØÌû¿ÉÄܺ¬ÓÐÐû´«ÄÚÈÝ
¡ï ¡ï ¡ï ¡ï ¡ï
swlhlbr: ½ð±Ò+5, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, thanks 2016-04-15 14:05:09
swlhlbr: ½ð±Ò+5, ·ÒëEPI+1, ¡ï¡ï¡ï¡ï¡ï×î¼Ñ´ð°¸, thanks 2016-04-15 14:05:09
|
Ä¿µÄ£ºÍ¨¹ý ½«ÃÅÕï ·¢ÉúµÄ Ò©Æ·²»Á¼·´Ó¦ ¼ÆÈë ÃÅÕï µç×Ó²¡Àú£¬±£Ö¤ÃÅÕï Ëù·¢Éú Ò©Æ·²»Á¼·´Ó¦µÄ ¿É×·ËÝÐÔ£¬ÔÚ¼ÓÇ¿ ÁÙ´² ¸öÌ廯 ÓÃÒ©°²È«µÄ ͬʱ ´Ù½ø ¶ÔÉÏÊÐÒ©Æ·µÄ °²È«ÖÊÁ¿¼à¿Ø£¬±£ÕÏ ¹ã´ó»¼ÕßµÄ ÓÃÒ©°²È«¡£·½·¨£º³ÉÁ¢ Æ·¹ÜȦ »î¶¯Ð¡×飬×ñÑ PDCA³ÌÐò£¬»îÓà Ʒ¹ÜȦ Æß´óÊÖ·¨£¬·ÖÎö ÃÅÕïÒ©Æ· ²»Á¼·´Ó¦ ÄÑÒÔËÝÔ´µÄ ÔÒò£¬Ì½Ë÷ ¶Ô²ß£¬ÓèÒÔ ÊµÊ©²¢ÆÀ¹À »î¶¯Ð§¹û¡£ ½á¹û£º±È½Ï »î¶¯Ç°¡¢ºó ¸÷Ïî Ò©Æ·²»Á¼·´Ó¦ ¿É ËÝÔ´Ö¸±ê ¾ùµÃµ½ÁË Ã÷ÏÔ¸ÄÉÆ£¬ÃÅÕïÒ©Æ· ²»Á¼·´Ó¦ ¼ÆÈë ²¡ÀúÂÊ ÓɸÄÉÆÇ°31%Éý ÖÁ¸ÄÉÆºó 90.1%£¬»î¶¯ºó ÃÅÕïÍËÒ©µÇ¼Ç±í È·ÈÏÇ©ÃûÂÊ ´ï87.2%£¬»î¶¯´ï±êÂÊ Îª105.6%¡£½áÂÛ£º±¾´Î Æ·¹ÜȦ»î¶¯ ÓÐЧµÄ Ìá¸ßÁË ÃÅÕïÒ©Æ·²»Á¼·´Ó¦ ¼ÆÈ벡ÀúµÄ ÖÊÁ¿£¬»¼Õß ³ÐŵǩÃû Ò»¶¨³Ì¶ÈµÄ ±£Ö¤ÁË ÃÅÕïÒ©Æ·²»Á¼·´Ó¦µÄ ÕæÊµÐÔ£¬±£Ö¤ÁË ÃÅÕïÒ©Æ·²» Á¼·´Ó¦µÄ ¿ÉËÝÔ´ÐÔ£¬Îª Ò©Æ·µÄ ÁÙ´²ºÏÀí ʹÓÃÌṩÁËÒÀ¾Ý¡£ Purpose: Guarantee the traceability of adverse drug reactions occurred during outpatient treatment by recording them into electronic medical record(EMR), and enhance monitoring the safety and quality of drugs on current market in the meantime of strengthening individual medication safety, so as to secure the medication safety for massive patients. Method: Establish activity groups of quality control circle, follow PDCA procedures and flexibly use the QC 7 basic tools, analyze the reason why adverse drug reactions can hardly be traced, explore countermeasures, implement activity and evaluate activity effect. Results: Through comparing the traceability indexes of adverse drug reactions before and after the implementation of activity, it shows that the traceability indexes have been improved, and the rate of successfully recording adverse drug reactions into EMR has been increased from 31% before improvement to 90.1% after improvement, in addition, the signature rate on drug withdrawal list after implementation of activity can reach 87.2%, and the rate of reaching the standard in activity reached 105.6%. Conclusion: The QCC activity effectively improved the quality of recording adverse drug reactions into EMR. Patient's commitment to signature on drug withdrawal list guarantees the authenticity and traceability of adverse drug reactions, providing basis for clinical rational drug use. ¹Ø¼ü´Ê£ºÒ©Æ·²»Á¼·´Ó¦£¬Æ·¹ÜȦ£¬ËÝÔ´ Keywords: Adverse Drug Reaction, Quality Control Circle; Traceability |
2Â¥2016-04-15 13:46:27














»Ø¸´´ËÂ¥